The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will ...

Good afternoon, and welcome to Tissue Regenix Group plc Interim Results Investor Presentation. [Operator Instructions] Before we begin, I would like to submit the following poll. I would now like to ...

LEEDS, United Kingdom--(BUSINESS WIRE)--Tissue Regenix Group plc, a UK- based regenerative medical company (AIM:TRX) announces completion of the acquisition of CellRight Technologies LLC, a US based ...

Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Group"), the regenerative medical devices company, today announces it has secured approval from the Noridian Healthcare Solutions and ...

With this approval, Tissue Regenix Wound Care Inc. increases the number of Medicare beneficiaries to whom DermaPure® is available by 2.5m. With prior approvals from Noridian Health Care Solutions, ...

Hardman & Co Research on Tissue Regenix (TRX): Continuing postive momentum 1H'23 18-Sep-2023 / 10:40 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co ...

Hardman & Co Research on Tissue Regenix (TRX): Six consecutive periods of >20% growth 10-Apr-2024 / 07:15 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co ...

The establishment of the JVA is an important milestone in the Group's overall commercialisation strategy, allowing Tissue Regenix to licence its patented dCELL® technology process for human tissue for ...

Tissue Regenix Group PLC Annual cash flow by MarketWatch. View LSW net cash flow, operating cash flow, operating expenses and cash dividends.

Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company, announces that it has further strengthened its position within the post-acute wound care ...

* TISSUE REGENIX GROUP - SECURED A U.S. GOVERNMENT BACKED LOAN TO ASSIST WITH POTENTIAL IMPACT OF ONGOING COVID-19 PANDEMIC * TISSUE REGENIX - Q1 REVENUES AS AT 31 MARCH INCREASED BY 18% YEAR-ON-YEAR, ...

10th Mar 2025 9:30 am RNS Form 8.5 (EPT/NON-RI) 6th Mar 2025 9:29 am RNS Form 8.5 (EPT/NON-RI) 5th Mar 2025 8:54 am RNS Form 8.5 (EPT/NON-RI) 4th Mar 2025 9:28 am RNS Form 8.5 (EPT/NON-RI) 3rd Mar ...